Breast Center Team at American Society of Clinical Oncology Annual Meeting 2015 – Key Happenings!

We are excited to announce the Weill Cornell Medical College Breast Center’s contributions to the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting next week!

Dr. Eleni Nackos (on behalf of Dr. Linda Vahdat) will be giving an oral presentation on the results from our phase 2 tetrathiomolybdate (TM) study. http://abstracts.asco.org/156/AbstView_156_151971.html

Dr. Tessa Cigler is chairing the Patient and Survivor Care session. Our abstract on cold caps was selected for a poster discussion session. http://abstracts.asco.org/156/AbstView_156_149240.html

Dr. Eleni Andreopoulou was selected by the International Development and Education Award (IDEA) group to mentor a physician from Morocco. Oncologists are selected by this group to host recipients for three-day visits following the ASCO meeting.

“The purpose of the IDEA program is to support the professional development of early-career oncologists in low- and middle-income countries around the world. The program pairs IDEA recipients with ASCO members in the United States or Canada who serve as their scientific mentors. Upon the mentees’ return to their home institution, it is expected that mentors and mentees remain in contact and pursue opportunities for consultation and collaboration.”

Dr. Anne Moore is chairing the Leadership Development Program presentation to the ASCO Board of Directors. The Leadership Development Program is a year-long program to learn leadership skills, gain exposure to the roles and mission of ASCO, and developing the future of cancer care. Dr. Moore is also joining the IDEA Working Group.

To view other abstracts from our studies:

PARP inhibitor ABT-888 http://abstracts.asco.org/156/AbstView_156_144933.html

Ovarian reserve and menses http://abstracts.asco.org/156/AbstView_156_147965.html

The METRIC study for metastatic triple negative breast cancer: http://abstracts.asco.org/156/AbstView_156_150265.html

IMMU study for metastatic triple negative breast cancer: http://abstracts.asco.org/156/AbstView_156_150673.html

Please find us on Twitter @CornellBreastCr & Facebook Weill Cornell Breast Center

ASCO Poster Presentation: ABT-888 (veliparib)+ Carboplatin in Stage IV BRCA-Associated Breast Cancer

Click to enlarge poster

In a poster presentation this week at the American Society of Clinical Oncology (ASCO) conference, researchers presented results from a nationwide study assessing a PARP inhibitor in BRCA-associated breast cancer. Dr. Tessa Cigler is the principal investigator of the study, “ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer,” at the Weill Cornell Breast Center.

Platinum and PARP inhibitors have demonstrated activity when used as single agent therapy in BRCA-associated breast cancer. However, there is limited data on using the two classes of medications together.

The study enrolled 22 women with BRCA-associated stage IV breast cancer to compare a combination of carboplatin (platinum-based chemotherapy) and ABT-888 (veliparib, a PARP inhibitor)  vs. single agent ABT-888, when ABT-88 is given every day.

The investigators found that the combination of caboplatin and ABT-888 is feasible, and, in preliminary analysis, the response and clinical benefit rates and duration are encouraging. The authors write that the results provide “justification to proceed with a planned phase II randomized single agent versus combination trial.”

Click here to read the published abstract.